Wiskott-Aldrich syndrome is a rare inherited immune disorder characterized by a triad of symptoms: eczema, immune deficiency and easy bruising and bleeding. This condition predominantly affects boys. Among the complications faced by individuals with this syndrome, recurrent severe infections stand out as particularly perilous. Now, a single infusion can transform the disease outlook, slashing life-threatening infections and offering an alternative to traditional transplants. This breakthrough marks a turning point for families facing Wiskott-Aldrich syndrome—and shows the power of precise genetic repair to rewrite a child’s fate.

A new study shows that infusing gene-corrected stem cells provides lasting protection. Among 27 patients followed for up to 13 years, severe infections fell from two per year before treatment to fewer than one per year between six and 18 months after treatment. The Food and Drug Administration approved the therapy in December 2025, citing a 93% drop in severe infections.

In Destiny’s Child No Longer: Rewriting Genetic Fate , we argue for a simple principle for inherited disease. Test the family, find the disease early and correct it before it causes lasting harm. Earlier stories in this series followed that principle from gene therapy for infants to gene therapy before birth . This study shows what that correction can achieve for an inherited immune disease, and why early diagnosis matters.

A Missing Protein In Every Blood Cell

Wiskott-Aldrich syndrome comes from changes in a single gene on the X chromosome. Boys have one X chromosome, so one faulty copy causes the disease. Girls have two, and a second healthy copy protects most of them. A mother can carry the gene without any symptoms and pass it to her sons.

The impacted gene carries instructions for a protein found in all blood cells. The protein helps each cell rebuild its internal scaffolding so that it can move, change shape and grip other cells. Without it, immune cells can’t latch onto the germs they’re meant to destroy. The result is a trio of problems: easy bleeding, stubborn eczema and repeated infections. Many patients also develop autoimmune disease, and they face a higher risk of lymphoma.

The established cure is a stem cell transplant from a healthy donor, which replaces the patient’s blood-forming system. Transplants now achieve about 90% overall survival at three to five years. However, many families can’t find a suitable match. Transplants carry the risks of rejection and graft-versus-host disease. Outcomes are worse for children treated after age five and for those with a less well-matched donor. Gene therapy offers another route, one that uses the patient’s own cells.

A Single Infusion Of Corrected Cells

The results held up over time. Overall survival was 96% at 1 year and 5 years. Severe infections decreased each year after five years of treatment. Moderate and severe bleeding events dropped from two per year before treatment to less than one in the first year. Platelet counts roughly tripled within a year, and patients stopped regular platelet transfusions approximately 47 days after treatment.

The gains also reached daily life. Of 23 patients with eczema before treatment, none had moderate or severe eczema from the first year onward, and none had any eczema from year six.

Every surviving patient stopped regular antibody infusions, and most produced protective responses to childhood vaccines. Three years after treatment, every patient had left the protected hospital environment; more than 80% were attending school or kindergarten and about half were playing sports. Hospitalizations fell from almost three per year before treatment to fewer than one per decade after year five.

Safety And Open Questions

The safety record also improves on earlier trials. The study found no leukemia and no sign that any single corrected cell had begun to multiply out of control. Analysis of where the gene landed in the DNA showed blood production drawn from many different corrected cells, with no sign that the virus had disturbed cancer genes.

The treatment still carries risks. Nineteen patients experienced serious adverse events. Most were infections. The study had no control group, which the authors note is inevitable in an ultra-rare disease. The FDA requires a 15-year follow-up study to track secondary cancer risk.

The path to approval is also unusual. The therapy began at an academic center, passed through pharmaceutical development and returned to Fondazione Telethon, an Italian nonprofit organization, which secured approval in Europe and the U.S. The FDA describes it as the first cell and gene therapy approved by a nonprofit applicant.

A durable treatment raises the stakes for early diagnosis. In this study, symptoms started at a median age of about four months, and diagnosis followed at a median age of one year. Genetic testing of mothers in affected families, and genome sequencing at birth , can identify boys with the disease before the first serious infection.

The lesson of this study reaches beyond one rare disease. A single infusion of a child’s own corrected cells can protect against infection, bleeding and eczema for more than a decade. When families learn of the diagnosis early, that protection can begin before the disease does its harm. A child previously defined by their genes can then grow up in school, on the playground and outside the hospital.